Price Reductions
Cross-source consensus on Price Reductions from 1 sources and 3 claims.
1 sources · 3 claims
How it works
Comparisons
Highlighted claims
- Reducing the EV price alone cannot make EV-Pem cost-effective at £30,000 per QALY. — Cost-effectiveness analysis of enfortumab vedotin and pembrolizumab versus chemotherapy for patients with untreated advanced urothelial cancer in the United Kingdom
- EV-Pem's high cost is driven by use of two high-cost agents. — Cost-effectiveness analysis of enfortumab vedotin and pembrolizumab versus chemotherapy for patients with untreated advanced urothelial cancer in the United Kingdom
- Concurrent reductions in both EV and pembrolizumab prices could theoretically make EV-Pem cost-effective at £30,000 per QALY. — Cost-effectiveness analysis of enfortumab vedotin and pembrolizumab versus chemotherapy for patients with untreated advanced urothelial cancer in the United Kingdom